Alphatec Spine Appoints New Vice President of Clinical, Quality and Regulatory
Michael J. Sarrasin Brings Over 20 Years of Clinical, Quality Assurance and Regulatory Experience in Medical Device and Life Sciences Industries
CARLSBAD, Calif., May 4, 2010 (GlobeNewswire via COMTEX News Network) — Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that Michael J. Sarrasin, who has over 20 years of clinical, quality assurance and regulatory affairs experience in the medical device and life sciences industries, has been named the Company’s Vice President, Clinical, Quality and Regulatory.
In this newly created position Mr. Sarrasin will be responsible for providing overall strategic direction and leadership to Alphatec Spine’s global clinical, quality assurance and regulatory affairs groups.
Most recently, Mr. Sarrasin served as Vice President, Regulatory Affairs and Quality Assurance for I-Flow Incorporated, a Lake Forest, CA-based medical device infusion pump manufacturer. In that position, he was responsible for formulating and implementing all of I-Flow’s regulatory and quality assurance strategies and programs.
Prior to joining I-Flow, Mr. Sarrasin served in vice-president level positions at several other medical device and life science companies, including Celerus Diagnostics Incorporated, DAKO USA Incorporated and LySonix Incorporated.
“We are pleased to have Mike Sarrasin join our management team and we feel as though he will be a tremendous asset for Alphatec Spine,” said Dirk Kuyper, the Company’s President and CEO. “He has over two decades of experience in the medical device and life science industries, and has led clinical, quality assurance and regulatory affairs departments for several successful companies. We believe that Mike’s expertise will provide us with the necessary leadership in an environment in which the path to regulatory approval for products seems to be becoming less predictable, especially as we continue to bring our novel and innovative products to both the U.S. and international spine market.”
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company’s mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient’s quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its subsidiary, Scient’x S.A., via a direct salesforce in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa, South America and Latin America. In Asia and Australia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc, and through Scient’x’s distributors in China, Korea and Australia.
The Alphatec Holdings, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3520
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Alphatec Holdings, Inc.